Literature DB >> 28449941

Is C-reactive protein ready for prime time in the selection of antidepressant medications?

Andrew H Miller1, Madhukar H Trivedi2, Manish K Jha2.   

Abstract

Entities:  

Keywords:  Biomarker; C-reactive protein; Depression; Dopamine; Serotonin; Treatment

Mesh：

Substances：

Year:  2017        PMID： 28449941     DOI： 10.1016/j.psyneuen.2017.04.006

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN： 0306-4530            Impact factor:   4.905


× No keyword cloud information.
  9 in total

1.  Sex differences in the association of baseline c-reactive protein (CRP) and acute-phase treatment outcomes in major depressive disorder: Findings from the EMBARC study.

Authors:  Manish K Jha; Abu Minhajuddin; Cherise Chin-Fatt; Tracy L Greer; Thomas J Carmody; Madhukar H Trivedi
Journal:  J Psychiatr Res       Date:  2019-03-20       Impact factor: 4.791

2.  The Sickness Behavior Inventory-Revised: Sickness behavior and its associations with depression and inflammation in patients with metastatic lung cancer.

Authors:  Daniel C McFarland; Leah E Walsh; Rebecca Saracino; Christian J Nelson; William Breitbart; Barry Rosenfeld
Journal:  Palliat Support Care       Date:  2021-06

3.  C-reactive protein and its association with depression in patients receiving treatment for metastatic lung cancer.

Authors:  Daniel C McFarland; Kelly Shaffer; William Breitbart; Barry Rosenfeld; Andrew H Miller
Journal:  Cancer       Date:  2018-12-06       Impact factor: 6.860

4.  Experimental Therapies for Treatment-Resistant Depression: "How do you decide when to go to an unproven or experimental therapy with patients that are treatment-resistant depression?"

Authors:  Manish K Jha; Madhukar H Trivedi
Journal:  Focus (Am Psychiatr Publ)       Date:  2018-07-18

5.  High S100B Levels Predict Antidepressant Response in Patients With Major Depression Even When Considering Inflammatory and Metabolic Markers.

Authors:  Ricard Navinés; Giovanni Oriolo; Igor Horrillo; Myriam Cavero; Bruno Aouizerate; Martin Schaefer; Lucile Capuron; J Javier Meana; Rocio Martin-Santos
Journal:  Int J Neuropsychopharmacol       Date:  2022-06-21       Impact factor: 5.678

6.  Chronically elevated depressive symptoms interact with acute increases in inflammation to predict worse neurocognition among people with HIV.

Authors:  Rowan Saloner; Emily W Paolillo; Robert K Heaton; David J Grelotti; Murray B Stein; Andrew H Miller; J Hampton Atkinson; Scott L Letendre; Ronald J Ellis; Igor Grant; Jennifer E Iudicello; David J Moore
Journal:  J Neurovirol       Date:  2021-01-06       Impact factor: 3.739

Review 7.  Personalized Antidepressant Selection and Pathway to Novel Treatments: Clinical Utility of Targeting Inflammation.

Authors:  Manish K Jha; Madhukar H Trivedi
Journal:  Int J Mol Sci       Date:  2018-01-12       Impact factor: 5.923

8.  Platelet-Derived Growth Factor as an Antidepressant Treatment Selection Biomarker: Higher Levels Selectively Predict Better Outcomes with Bupropion-SSRI Combination.

Authors:  Manish K Jha; Abu Minhajuddin; Bharathi S Gadad; Madhukar H Trivedi
Journal:  Int J Neuropsychopharmacol       Date:  2017-11-01       Impact factor: 5.176

9.  Higher S100B Levels Predict Persistently Elevated Anhedonia with Escitalopram Monotherapy Versus Antidepressant Combinations: Findings from CO-MED Trial.

Authors:  Manish K Jha; Abu Minhajuddin; Bharathi S Gadad; Cherise Chin Fatt; Madhukar H Trivedi
Journal:  Pharmaceuticals (Basel)       Date:  2019-12-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.